Image: Shutterstock
February 6, 2024 07:28 AM ESTUpdated 10:40 AM
Pharma

Lil­ly's weight loss drug Zep­bound gen­er­ates $175M with­in weeks as Moun­jaro sales al­so soar

Katherine Lewin

News Reporter

Eli Lil­ly’s weight loss drug Zep­bound has pulled in $175.8 mil­lion in rev­enue since its ap­proval in No­vem­ber, the In­di­anapo­lis phar­ma said Tues­day in its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times